Efficacy and Safety of Guselkumab in Patients With Active Psoriatic Arthritis who are Inadequate Responders to Tumor Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)
COATES L., Gossec L., Theander E., Bergmans P., Neuhold M., Karyekar CS., Shawi M., Noel W., Schett G., McInnes IB.